Early versus delayed autologous stem cell transplantation in patients receiving novel therapies for Multiple Myeloma

Autologous stem cell transplant (ASCT) is an effective treatment for multiple myeloma (MM). However the timing of ASCT in the era of novel agents (lenalidomide, thalidomide, bortezomib) is unknown. We retrospectively reviewed the outcome of MM patients who received novel agent based induction treatm...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Dunavin, Neil C., Wei, Lai, Elder, Patrick, Phillips, Gary S, Benson, Don M, Hofmeister, Craig C., Penza, Sam, Greenfield, Carli, Rose, Karen S., Rieser, Gisele, Merritt, Lisa, Ketcham, Jill, Heerema, Nyla, Byrd, John C., Devine, Steven M., Efebera, Yvonne A.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3769940/
https://ncbi.nlm.nih.gov/pubmed/23194056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.751528
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items